• Home
• GJF
  • Joint Wound Care Formulary
  • . . . Introduction
  • 1. Gastro-Intestinal System
  • 2. Cardiovascular System
  • 3. Respiratory System
  • 4. Central Nervous System
    • 4.1 Hypnotics and anxiolytics
    • 4.2 Drugs used in psychoses and related disorders
    • 4.3 Antidepressants
    • 4.4 CNS stimulants and other drugs used for ADHD
    • 4.5 Drugs used in the treatment of obesity
      • 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract
      • 4.5.2 Centrally Acting Appetite Suppressants
    • 4.6 Drugs used in nausea and vertigo
    • 4.7 Analgesics
    • 4.8 Antiepileptics
    • 4.9 Drugs used in parkinsonism and related disorders
    • 4.10 Drugs used in substance dependence
    • 4.11 Drugs for dementia
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary Tract Disorders
  • 8. Malignant Disease and Immunosuppresion
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Disease
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological products and vaccines
  • 15. Anaesthesia
  • Appendix 1. Drugs for emergency use in General Practice
  • Appendix 2. Palliative Care
  • Appendix 3. Oral Nutritional Supplements (ONS)
  • Appendix 4. Gluten-free and cow's milk protein-free products
  • Medicines No Longer included in the GJF
  • Medicines not recommended for use in NHS Grampian
• eGJF
• Medicines Management
• Policies
• News Letters
• Shared Care Protocols
• Patient Group Directions

4.5.2 Centrally acting appetite suppressants

Sibutramine (dexfenfluramine and fenfluramine) has been withdrawn because the benefits of treatment does not outweigh the risk of serious adverse effects.

21st January 2010: The European Medicines Agency (EMA) has completed a review of the obesity medicine sibutramine (Reductil®) and has found that the cardiovascular risks of sibutramine outweigh its benefits. The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended suspension of the marketing authorisation for this medicine across the European Union.

Further information is available on the MHRA and EMA websites.

Previous: Anti-obesity drugs acting on the GI tract | Top | Next: Drugs used in nausea and vertigo